Early laboratory results in mice show the drug PXS-5505 increases survival when combined with chemotherapy in the treatment of an aggressive form of pancreatic cancer.
UNSW Sydney and the Garvan Institute of Medical Research researchers will lead the program, thanks to a $3.75 million grant from the Cancer Institute NSW.
UNSW scientists have grown human pancreatic cancer tumours in the lab – their model is the first of its kind, with important future clinical implications.
